Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343364 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
A Phase 1 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05343364 is a Phase 1 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT05343364, a Phase 1 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
Interventions
- DRUG Vonoprazan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05343364
The ClinicalTrials.gov registry entry for NCT05343364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vonoprazan is the first listed.
NCT05343364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05343364 about?
NCT05343364 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease". The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
What is the current status of trial NCT05343364?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-05-09. Estimated completion is 2023-06-13.
What interventions are being tested in trial NCT05343364?
The interventions under investigation include: Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT05343364?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.